Cargando…
Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
OBJECTIVES: To identify combined clinical, radiomic, and delta-radiomic features in metastatic gastroesophageal adenocarcinomas (GEAs) that may predict survival outcomes. METHODS: A total of 166 patients with metastatic GEAs on palliative chemotherapy with baseline and treatment/follow-up (8–12 week...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461093/ https://www.ncbi.nlm.nih.gov/pubmed/37645426 http://dx.doi.org/10.3389/fonc.2023.892393 |
_version_ | 1785097784978833408 |
---|---|
author | Krishna, Satheesh Sertic, Andrew Liu, Zhihui (Amy) Liu, Zijin Darling, Gail E. Yeung, Jonathon Wong, Rebecca Chen, Eric X. Kalimuthu, Sangeetha Allen, Michael J. Suzuki, Chihiro Panov, Elan Ma, Lucy X. Bach, Yvonne Jang, Raymond W. Swallow, Carol J. Brar, Savtaj Elimova, Elena Veit-Haibach, Patrick |
author_facet | Krishna, Satheesh Sertic, Andrew Liu, Zhihui (Amy) Liu, Zijin Darling, Gail E. Yeung, Jonathon Wong, Rebecca Chen, Eric X. Kalimuthu, Sangeetha Allen, Michael J. Suzuki, Chihiro Panov, Elan Ma, Lucy X. Bach, Yvonne Jang, Raymond W. Swallow, Carol J. Brar, Savtaj Elimova, Elena Veit-Haibach, Patrick |
author_sort | Krishna, Satheesh |
collection | PubMed |
description | OBJECTIVES: To identify combined clinical, radiomic, and delta-radiomic features in metastatic gastroesophageal adenocarcinomas (GEAs) that may predict survival outcomes. METHODS: A total of 166 patients with metastatic GEAs on palliative chemotherapy with baseline and treatment/follow-up (8–12 weeks) contrast-enhanced CT were retrospectively identified. Demographic and clinical data were collected. Three-dimensional whole-lesional radiomic analysis was performed on the treatment/follow-up scans. “Delta” radiomic features were calculated based on the change in radiomic parameters compared to the baseline. The univariable analysis (UVA) Cox proportional hazards model was used to select clinical variables predictive of overall survival (OS) and progression-free survival (PFS) (p-value <0.05). The radiomic and “delta” features were then assessed in a multivariable analysis (MVA) Cox model in combination with clinical features identified on UVA. Features with a p-value <0.01 in the MVA models were selected to assess their pairwise correlation. Only non-highly correlated features (Pearson’s correlation coefficient <0.7) were included in the final model. Leave-one-out cross-validation method was used, and the 1-year area under the receiver operating characteristic curve (AUC) was calculated for PFS and OS. RESULTS: Of the 166 patients (median age of 59.8 years), 114 (69%) were male, 139 (84%) were non-Asian, and 147 (89%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. The median PFS and OS on treatment were 3.6 months (95% CI 2.86, 4.63) and 9 months (95% CI 7.49, 11.04), respectively. On UVA, the number of chemotherapy cycles and number of lesions at the end of treatment were associated with both PFS and OS (p < 0.001). ECOG status was associated with OS (p = 0.0063), but not PFS (p = 0.054). Of the delta-radiomic features, delta conventional HUmin, delta gray-level zone length matrix (GLZLM) GLNU, and delta GLZLM LGZE were incorporated into the model for PFS, and delta shape compacity was incorporated in the model for OS. Of the treatment/follow-up radiomic features, shape compacity and neighborhood gray-level dependence matrix (NGLDM) contrast were used in both models. The combined 1-year AUC (Kaplan–Meier estimator) was 0.82 and 0.81 for PFS and OS, respectively. CONCLUSIONS: A combination of clinical, radiomics, and delta-radiomic features may predict PFS and OS in GEAs with reasonable accuracy. |
format | Online Article Text |
id | pubmed-10461093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104610932023-08-29 Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma Krishna, Satheesh Sertic, Andrew Liu, Zhihui (Amy) Liu, Zijin Darling, Gail E. Yeung, Jonathon Wong, Rebecca Chen, Eric X. Kalimuthu, Sangeetha Allen, Michael J. Suzuki, Chihiro Panov, Elan Ma, Lucy X. Bach, Yvonne Jang, Raymond W. Swallow, Carol J. Brar, Savtaj Elimova, Elena Veit-Haibach, Patrick Front Oncol Oncology OBJECTIVES: To identify combined clinical, radiomic, and delta-radiomic features in metastatic gastroesophageal adenocarcinomas (GEAs) that may predict survival outcomes. METHODS: A total of 166 patients with metastatic GEAs on palliative chemotherapy with baseline and treatment/follow-up (8–12 weeks) contrast-enhanced CT were retrospectively identified. Demographic and clinical data were collected. Three-dimensional whole-lesional radiomic analysis was performed on the treatment/follow-up scans. “Delta” radiomic features were calculated based on the change in radiomic parameters compared to the baseline. The univariable analysis (UVA) Cox proportional hazards model was used to select clinical variables predictive of overall survival (OS) and progression-free survival (PFS) (p-value <0.05). The radiomic and “delta” features were then assessed in a multivariable analysis (MVA) Cox model in combination with clinical features identified on UVA. Features with a p-value <0.01 in the MVA models were selected to assess their pairwise correlation. Only non-highly correlated features (Pearson’s correlation coefficient <0.7) were included in the final model. Leave-one-out cross-validation method was used, and the 1-year area under the receiver operating characteristic curve (AUC) was calculated for PFS and OS. RESULTS: Of the 166 patients (median age of 59.8 years), 114 (69%) were male, 139 (84%) were non-Asian, and 147 (89%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. The median PFS and OS on treatment were 3.6 months (95% CI 2.86, 4.63) and 9 months (95% CI 7.49, 11.04), respectively. On UVA, the number of chemotherapy cycles and number of lesions at the end of treatment were associated with both PFS and OS (p < 0.001). ECOG status was associated with OS (p = 0.0063), but not PFS (p = 0.054). Of the delta-radiomic features, delta conventional HUmin, delta gray-level zone length matrix (GLZLM) GLNU, and delta GLZLM LGZE were incorporated into the model for PFS, and delta shape compacity was incorporated in the model for OS. Of the treatment/follow-up radiomic features, shape compacity and neighborhood gray-level dependence matrix (NGLDM) contrast were used in both models. The combined 1-year AUC (Kaplan–Meier estimator) was 0.82 and 0.81 for PFS and OS, respectively. CONCLUSIONS: A combination of clinical, radiomics, and delta-radiomic features may predict PFS and OS in GEAs with reasonable accuracy. Frontiers Media S.A. 2023-08-14 /pmc/articles/PMC10461093/ /pubmed/37645426 http://dx.doi.org/10.3389/fonc.2023.892393 Text en Copyright © 2023 Krishna, Sertic, Liu, Liu, Darling, Yeung, Wong, Chen, Kalimuthu, Allen, Suzuki, Panov, Ma, Bach, Jang, Swallow, Brar, Elimova and Veit-Haibach https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Krishna, Satheesh Sertic, Andrew Liu, Zhihui (Amy) Liu, Zijin Darling, Gail E. Yeung, Jonathon Wong, Rebecca Chen, Eric X. Kalimuthu, Sangeetha Allen, Michael J. Suzuki, Chihiro Panov, Elan Ma, Lucy X. Bach, Yvonne Jang, Raymond W. Swallow, Carol J. Brar, Savtaj Elimova, Elena Veit-Haibach, Patrick Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma |
title | Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma |
title_full | Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma |
title_fullStr | Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma |
title_full_unstemmed | Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma |
title_short | Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma |
title_sort | combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461093/ https://www.ncbi.nlm.nih.gov/pubmed/37645426 http://dx.doi.org/10.3389/fonc.2023.892393 |
work_keys_str_mv | AT krishnasatheesh combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT serticandrew combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT liuzhihuiamy combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT liuzijin combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT darlinggaile combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT yeungjonathon combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT wongrebecca combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT chenericx combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT kalimuthusangeetha combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT allenmichaelj combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT suzukichihiro combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT panovelan combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT malucyx combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT bachyvonne combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT jangraymondw combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT swallowcarolj combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT brarsavtaj combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT elimovaelena combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma AT veithaibachpatrick combinationofclinicalradiomicanddeltaradiomicfeaturesinsurvivalpredictionofmetastaticgastroesophagealadenocarcinoma |